BR112013024968A2 - composição farmacêutica, e, método de tratamento de uma convulsão - Google Patents
composição farmacêutica, e, método de tratamento de uma convulsãoInfo
- Publication number
- BR112013024968A2 BR112013024968A2 BR112013024968A BR112013024968A BR112013024968A2 BR 112013024968 A2 BR112013024968 A2 BR 112013024968A2 BR 112013024968 A BR112013024968 A BR 112013024968A BR 112013024968 A BR112013024968 A BR 112013024968A BR 112013024968 A2 BR112013024968 A2 BR 112013024968A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- seizure
- treating
- benzodiazepine
- administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469940P | 2011-03-31 | 2011-03-31 | |
| PCT/US2012/031453 WO2012135619A2 (en) | 2011-03-31 | 2012-03-30 | Intranasal benzodiazepine pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013024968A2 true BR112013024968A2 (pt) | 2016-12-20 |
Family
ID=46928023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013024968A BR112013024968A2 (pt) | 2011-03-31 | 2012-03-30 | composição farmacêutica, e, método de tratamento de uma convulsão |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120252793A1 (https=) |
| EP (1) | EP2691100A4 (https=) |
| JP (1) | JP2014509655A (https=) |
| KR (1) | KR20140029426A (https=) |
| CN (1) | CN103619338B (https=) |
| AR (1) | AR085927A1 (https=) |
| AU (1) | AU2012236334B2 (https=) |
| BR (1) | BR112013024968A2 (https=) |
| CA (1) | CA2831308A1 (https=) |
| MX (1) | MX357800B (https=) |
| PH (2) | PH12013501915A1 (https=) |
| RU (2) | RU2013148120A (https=) |
| SG (2) | SG193958A1 (https=) |
| TW (1) | TWI601532B (https=) |
| WO (1) | WO2012135619A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| JP5929800B2 (ja) * | 2012-04-03 | 2016-06-08 | コニカミノルタ株式会社 | 定着液および画像形成方法 |
| US11020403B2 (en) * | 2017-06-02 | 2021-06-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| US11278492B2 (en) | 2018-01-05 | 2022-03-22 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| JP7492918B2 (ja) | 2018-06-04 | 2024-05-30 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物 |
| CN111529489A (zh) * | 2020-04-17 | 2020-08-14 | 山东省药学科学院 | 一种含有地西泮的鼻腔喷雾剂 |
| EP4458414A3 (en) | 2020-12-04 | 2025-01-01 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| CN118765194A (zh) | 2021-12-28 | 2024-10-11 | 阿尔库缇斯生物疗法股份有限公司 | 局部罗氟司特气溶胶泡沫 |
| EP4586999A1 (en) | 2022-09-15 | 2025-07-23 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| MXPA02001612A (es) * | 1999-07-26 | 2003-10-14 | Sk Corp | Composiciones anti-convulsivas transnasales y procedimiento modular. |
| EP1539285B2 (en) * | 2002-09-03 | 2011-10-12 | Pharmacure Health Care AB | Nasal sprays |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US7745430B2 (en) * | 2006-11-15 | 2010-06-29 | Sk Holdings Co., Ltd. | Transnasal anticonvulsive pharmaceutical composition |
| NZ583265A (en) * | 2007-08-31 | 2012-01-12 | Archimedes Dev Ltd | Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| WO2011034920A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
-
2012
- 2012-03-30 PH PH1/2013/501915A patent/PH12013501915A1/en unknown
- 2012-03-30 SG SG2013072319A patent/SG193958A1/en unknown
- 2012-03-30 WO PCT/US2012/031453 patent/WO2012135619A2/en not_active Ceased
- 2012-03-30 BR BR112013024968A patent/BR112013024968A2/pt not_active Application Discontinuation
- 2012-03-30 AU AU2012236334A patent/AU2012236334B2/en not_active Ceased
- 2012-03-30 CN CN201280017015.8A patent/CN103619338B/zh active Active
- 2012-03-30 MX MX2013011336A patent/MX357800B/es active IP Right Grant
- 2012-03-30 KR KR1020137028968A patent/KR20140029426A/ko not_active Ceased
- 2012-03-30 US US13/435,837 patent/US20120252793A1/en not_active Abandoned
- 2012-03-30 TW TW101111309A patent/TWI601532B/zh not_active IP Right Cessation
- 2012-03-30 RU RU2013148120/15A patent/RU2013148120A/ru not_active Application Discontinuation
- 2012-03-30 RU RU2018135967A patent/RU2018135967A/ru not_active Application Discontinuation
- 2012-03-30 CA CA2831308A patent/CA2831308A1/en not_active Abandoned
- 2012-03-30 SG SG10201602176RA patent/SG10201602176RA/en unknown
- 2012-03-30 EP EP12763553.0A patent/EP2691100A4/en not_active Ceased
- 2012-03-30 JP JP2014502835A patent/JP2014509655A/ja active Pending
- 2012-04-03 AR ARP120101144A patent/AR085927A1/es unknown
-
2014
- 2014-01-14 US US14/154,575 patent/US20140128381A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/198,884 patent/US20170151258A1/en not_active Abandoned
-
2017
- 2017-09-15 PH PH12017501688A patent/PH12017501688A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013011336A (es) | 2013-12-16 |
| SG10201602176RA (en) | 2016-04-28 |
| US20120252793A1 (en) | 2012-10-04 |
| RU2018135967A (ru) | 2018-11-14 |
| TWI601532B (zh) | 2017-10-11 |
| CA2831308A1 (en) | 2012-10-04 |
| EP2691100A2 (en) | 2014-02-05 |
| WO2012135619A2 (en) | 2012-10-04 |
| SG193958A1 (en) | 2013-11-29 |
| AU2012236334B2 (en) | 2017-02-16 |
| PH12017501688A1 (en) | 2018-09-10 |
| EP2691100A4 (en) | 2014-09-24 |
| MX357800B (es) | 2018-07-25 |
| TW201302204A (zh) | 2013-01-16 |
| CN103619338B (zh) | 2016-06-22 |
| WO2012135619A3 (en) | 2012-11-22 |
| AU2012236334A1 (en) | 2013-10-10 |
| KR20140029426A (ko) | 2014-03-10 |
| AR085927A1 (es) | 2013-11-06 |
| HK1195252A1 (zh) | 2014-11-07 |
| CN103619338A (zh) | 2014-03-05 |
| JP2014509655A (ja) | 2014-04-21 |
| RU2013148120A (ru) | 2015-05-10 |
| US20140128381A1 (en) | 2014-05-08 |
| US20170151258A1 (en) | 2017-06-01 |
| PH12013501915A1 (en) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013024968A2 (pt) | composição farmacêutica, e, método de tratamento de uma convulsão | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| UY33370A (es) | Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización | |
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| GB201118656D0 (en) | New compounds | |
| MY169987A (en) | Selective pi3k delta inhibitors | |
| MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
| EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| EA201600096A1 (ru) | Бензил-1н-пиразол[3,4-b]пиридины и их применение | |
| IN2015DN01151A (https=) | ||
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| WO2013147649A3 (ru) | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ | |
| MX2013001842A (es) | Composiciones de plasma rico en plaquetas. | |
| IN2014CN04634A (https=) | ||
| MX364220B (es) | Metodos de tratamientos de fibrosis. | |
| EA201290603A1 (ru) | Способ лечения | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP3071214A4 (en) | Salacia compositions, methods of treatment by their administration, and methods of their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |